Plain-English translation of NCT07404865 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called to see if it can help treat primary Sjögren's disease, an autoimmune condition where the immune system attacks the glands that produce tears and saliva. works by calming down overactive B cells—immune cells that are misbehaving in Sjögren's disease—so they stop attacking your own body. This medication has been designed to reduce the harmful signals that make these immune cells overactive.
Primary Sjögren's disease currently has limited treatment options that directly target the root immune problem. Researchers believe this medication could help by stopping the specific immune signals that drive the disease, potentially reducing symptoms and improving quality of life for patients who are not getting adequate relief from existing treatments.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication or a placebo (a harmless inactive substance) and take it as directed over the study period. The trial is double-blinded, meaning neither you nor the researchers will know which treatment you're receiving, helping ensure fair results. You will have regular study visits where doctors monitor your symptoms, disease activity, and any side effects to determine whether the medication is helping.
AI-generated summary from trial data · Aug 23, 2026 · Not medical advice
United States